Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuPath HealthTSXV:NPTH 39 EBITDA Margin % is 6.80% as of Jun. 2026, which is 481% above its 10-year median of 1.17. GuruFocus rates TSXV:NPTH with a GF Score™ of 39/100 and a GF Value™ of C$0.25 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 670 Healthcare Providers & Services companies, NeuPath Health ranks worse than 67.46% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. NeuPath Health's EBITDA for the
three
months ended in Jun. 2026 was C$1.58 Mil. NeuPath Health's Revenue for the
three
months ended in Jun. 2026 was C$23.23 Mil. Therefore, NeuPath Health's EBITDA margin for the quarter that ended in Jun. 2026 was 6.80%.
NeuPath Health (TSXV:NPTH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
NeuPath Health EBITDA Margin % Related Terms
NeuPath Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for NeuPath Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:NPTH vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, NeuPath Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuPath Health EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NeuPath Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where NeuPath Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuPath Health (TSXV:NPTH) has a EBITDA Margin % of 6.80% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NeuPath Health and its competitors. This is 481% above median its historical median of 1.17. According to the industry distribution chart, NeuPath Health ranks #452 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 67.5%.
Is NeuPath Health's EBITDA Margin % too high?
NeuPath Health's current EBITDA Margin % of 6.80% is 481% above median its 10-year median of 1.17. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. NeuPath Health's value of 6.80% is 33.6% below this industry median. Based on the distribution chart, NeuPath Health ranks #452 out of 670 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, NeuPath Health has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuPath Health's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, NeuPath Health ranks #452 out of 670 companies for EBITDA Margin %. This places NeuPath Health in the lower half of its industry. The industry median EBITDA Margin % is 10.24. NeuPath Health's value of 6.80% is 33.6% below this benchmark. While the company's 10-year median is 1.17 vs. the industry median of 10.24, NeuPath Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuPath Health's current EBITDA Margin % of 6.80% is 33.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on NeuPath Health and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuPath Health's current EBITDA Margin % is 6.80%, which is 481% above median its own 10-year median of 1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuPath Health stock overvalued right now?
Based on GuruFocus' analysis, NeuPath Health (TSXV:NPTH) is currently considered Significantly Overvalued. The stock's GF Value™ is C$0.25, compared to a current price of C$0.55 — trading 120% above its estimated fair value. The current EBITDA Margin % is 6.80%, which is 481% above median its 10-year median of 1.17 and 33.6% below the Healthcare Providers & Services industry median of 10.24. NeuPath Health's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For NeuPath Health (TSXV:NPTH), the current EBITDA Margin % is 6.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuPath Health (TSXV:NPTH) Overvalued in 2026?
Based on GuruFocus' analysis, NeuPath Health stock appears to be overvalued.
The current stock price of C$0.55 is trading 120% above its estimated GF Value™ of C$0.25.
GuruFocus considers NeuPath Health to be Significantly Overvalued.
Key valuation signals for TSXV:NPTH:
EBITDA Margin %: 6.80% (481% above median its 10-year median of 1.17)
GF Value™: C$0.25 vs. price of C$0.55 (120% above fair value)
Industry Position: 33.6% below the Healthcare Providers & Services median (#452 of 670)
No single metric tells the full story. See the TSXV:NPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuPath Health Inc operates an end-to-end, integrated network of healthcare businesses. It utilizes research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by acute and chronic musculoskeletal conditions, including chronic pain, spinal injuries, sports-related injuries, and concussions. It operates an interdisciplinary network of medical clinics in Ontario and Alberta, in addition to an independent medical assessment business with a national network of healthcare providers. Its medical clinics provide comprehensive assessments and rehabilitation services to clients with chronic pain, musculoskeletal or back injuries, sports-related injuries, and concussions. The company operates in one industry segment: medical services.
39GF Score
Get the complete analysis for TSXV:NPTH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NPTH has been successfully added to your 
